SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 14.7% Stake in ARCELLX INC Common Stock
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a combined beneficial ownership of 14.7% of ARCELLX INC's common stock as of December 31, 2024.
Summary
- FMR LLC and Abigail P. Johnson jointly filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in ARCELLX INC.
- As of December 31, 2024, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 7,956,633.28 shares of ARCELLX INC Common Stock.
- This represents 14.7% of the class of ARCELLX INC's Common Stock.
- FMR LLC holds sole voting power over 7,955,204.00 shares and sole dispositive power over 7,956,633.28 shares.
- Abigail P. Johnson holds sole dispositive power over 7,956,633.28 shares, with no sole or shared voting power reported directly.
- FMR LLC is classified as a parent holding company or control person (Rule 13d-1(b)(1)(ii)(G)).
- Abigail P. Johnson is identified as an individual, and also as a Director, Chairman, and Chief Executive Officer of FMR LLC.
- Several FMR LLC subsidiaries, including Fidelity Management & Research Company LLC (which beneficially owns 5% or more), are identified as entities that beneficially own shares.
- The Johnson family, including Abigail P. Johnson, are predominant owners of FMR LLC's Series B voting common shares (representing 49% of voting power) and may form a controlling group through a shareholders' voting agreement.
Sentiment
Score: 5
Explanation: Neutral. This is a factual disclosure of beneficial ownership, not a performance report or strategic announcement. It indicates a significant institutional stake, which can be viewed positively by some, but the filing itself is neutral in tone and content regarding the issuer's operations.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by a major institutional investor (FMR LLC) in a publicly traded company (ARCELX INC). It does not provide specific insights into broader industry trends but highlights significant institutional interest in the biotechnology sector.
Stakeholder Impact
- Shareholders: Provides transparency on significant institutional ownership, which can influence market perception and liquidity.
- Investors: Informs the market about a major investor's stake, potentially signaling confidence or a long-term holding strategy.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of FMR LLC. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number -23-000003) was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number -23-000038) for Abigail P. Johnson was incorporated by reference. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-02-11 | Date of filing of this Schedule 13G Amendment No. 3. |
Keywords
ARCELX INC, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Stake, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.